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lished, the schedules listed have become
outdated. Here, however the authors are
to be congratulated on presenting regimens
in general, and combinations in particular,
that are currently in use at this moment.
The book will appeal to all involved in the
management of malignant disease and is
particularly recommended to those in junior
grades. It should provide a useful reference
to those in other disciplines and find a place
in medical libraries.
P. M. WILKINSON
Cancer of the Lung. H. G. SEYDEL,
A. CHAIT and J. T. GMELICH (1975).
New York: John Wiley & Sons. Price
£14.00 net.
This is another book on cancer of the
lung. It comes from the USA, is of multiple
authorship, and is well produced. The
authors have succeeded in their obvious
intention to review the subject comprehen-
sively yet compactly, and it is fair to say
that, as a presentation of known fact and
of contemporary North American opinion
and practice, it could hardly be improved.
The bibliography includes references up to
1974.
Subjects such as incidence, aetiology,
natural history, early detection, lymphatic
spread, staging, and associated medical
conditions each have a chapter to themselves,
and on the whole are competently reviewed,
though the section on endocrine manifesta-
tions could have been expanded, and
reference to the neuropathies is perfunctory.
The presentation of the chapter on staging
emphasizes the impractical complexity of
the UICC TNM classification, though the
proposed NCI classification is hardly better,
since it is based on the UICC system.
The discussion of pathology is full, de-
tailed and clear, and emphasizes the difficulty
of classification ofsuch pleomorphic tumours.
The contribution of diagnostic radiology is
also very well described, and a particularly
good feature of this chapter is the well-
balanced evaluation of the less common
procedures such as arteriography and veno-
graphy.
Chemotlherapy is allocatedI tw-ro pages
oftext, ancd, togetlher wi-itlh a page on imimnUniio-
therapy, forms a chapter titled ' Specific
Medical Management". Its brevity is sur-
44
prising in view of the enormous amount
of work done in the USA on chemotherapy,
and perhaps reflects disillusionment with
the very limited value of chemotherapy
for lung cancer. It seems that the general
conclusions to be drawn are that cyclo-
phosphamide used as a single agent for the
late case can be useful, that the slightly
greater effect of combination chemotherapy
is out-weighed by the greater toxicity, and
that chemotherapy in combination with
surgery or radiotherapy is of no value.
There has been no real progress in the
treatment of patients with lung cancer
for many years, and anyone with a special
interest in the disease approaches the
chapters on management with the hope of
finding something new which might en-
courage optimism. Sadly, overall survival
rates remain unchanged, though there has
certainly been a little progress, mainly
amongst surgeons, in a more precise know-
ledge of what radical treatment can achieve.
The relatively short chapter on surgical
treatment is perhaps the best part of the
book: it is succinct and authoritative.
There is now full awareness ofthe importance
of pre-operative staging, especially since
mediastinoscopy has become common, and
a realization that only " early " cases benefit
from resection. The result has been a
significant increase in survival rates for
patients undergoing resection, and a pro-
portionate decrease in the thoracotomy-only
figures. This does not mean, of course,
that more patients are being cured of cancer,
but it does mean that fewer patients have
an unnecessary thoracotoImy. The general
trend towards conservative resection is con-
firmed. It seems that the indications for
surgery, and the limits of its usefulness, are
now fairly well defined.
One might have expected that the
selection of cases for radical radiotherapy
with curative intent would have been
refined in the same way, but the opposite
seems to be true. The indications for
radical x-ray treatment include patients
with extensive mediastinal node involve-
ment, and even those with metastases in
the supraclavicular nodes. It seems that
treatment is relatively standardized to a
parallel pair of fields enclosing the primary
tumour and most of the mediastinumn. Field
sizes al-e not usually given, but judging by
the diagrams must be of the order of 15 x 10672 BOOK REVIEWS
cm or larger. A dose of about 4500 rad is
given in 4-5 weeks, followed by another
1500-2000 rad given by arc therapy to a
smaller volume which is largely determined
by the appearance of the chest x-ray 4 weeks
after the treatment began. The total treat-
ment time is of the order of 6 weeks. It is
difficult to estimate the described dosage
accurately, since it is always given as a
number of rads, the field size and overall
time being rarely mentioned. It is assumed
that dosage is based on an input rate of
1000 rad per week.
This treatment policy is very different
from British practice, which is based on
the principle of higher doses to smaller
volumes of tissue, and therefore limits
radical treatment to earlier cases. For this
reason the radiotherapy section of the book
is not of value to British students of radio-
therapy, though the remainder of the book
is a useful contribution to the literature.
E. SHERRAH-DAVIES
Cell Survival after low Doses of Radia-
ation: Theoretical and Clinical Impli-
cations. Proceedings ofthe 6th L. H. Gray
Conference, London, 1974. Ed. T. ALPER
(1975). Institute of Physics: John Wiley.
Pp. xiv + 397. Price £13.50 net.
It has taken the majority of radio-
biologists about 18 years to concentrate
their attention on dose-cell survival relation-
ships in the therapeutic range of 200-300 rad
per fraction. This omission can now be
corrected with the proceedings of this
conference, where these relationships were
discussed rigorously. Forty-five contributed
papers were arranged in 6 sessions, ranging
from fundamental aspects to clinical applica-
tions. The influence of the physical sciences
in biology is shown vividly in this conference:
20% of the 142 participants had Physics or
Medical Physics departmental addresses.
The first two sessions dealt with the statistical
problems involved in measuring small frac-
tions ofcell killing, and with biomathematical
models for cell survival as a function of
dose.
The critical lesion for cell death (if indeed
there is only one type applicable to the
whole cell survival curve) is still unknown,
but DNA breaks and consequent chromo-
some breaks are implicated to a great
extent and are at the head of the current
list. At least 7 dose-response relationships
for cell survival are mentioned-these are
usually 2- or 3-parameter functions and their
biophysical basis and degree of fit to experi-
mental data are the main criteria for accept-
ance and use for comparative purposes and
interpretation. Thus, a " good " model in
this field combines two virtues: few variables
and low chi-squared. Nearly all cell survival
data show an initial slope at low dose,
i.e. there is no true threshold. How much
of this, if any, is due to the inhomogeneity
of the radiation dose at the molecular level,
or the presence of a radiosensitive fraction
of cells, is not fully known.
Modifications to the initial slope by 02
and other chemical sensitizers are described
at length. Results vary from simple dose
modification to unexpected protection at
very low doses, and definitive experiments
are hampered by the technical difficulties
involved in these measureinents. The scope
ofthe meeting was large enough to encompass
other cells than mammalian (e.g. bacteria,
plant cells, yeast) and other radiations than
x-rays (e.g. 125I, u.v., neutrons).
Tumour cell responses for low dose in vivo
irradiations are covered with respect to
dose-rate, fractionation and high pressure
02. The difference in response ofchronically
and acutely hypoxic cells, and the important
question of whether hypoxic cells really
are a major problem in human tumour
radiotherapy, were discussed but still remain
unexplained.
The interpretation of multi-fraction ex-
periments on normal tissues formed the
final session. A cell survival curve can be
deduced from multi-fraction data when
certain assumptions are made, but it must
not be forgotten that this is the " effective "
cell survival curve for dose fractionation,
which may differ, for many reasons, from
that determined for single exposures in a
well controlled situation. Therefore, the
interpretation in terms of the same model
functions has inherent problems. Repopula-
tion during fractionation is allowed for in
such a deduction, and this is of course
unnecessary, or at least easier, with the
slow turnover tissues (e.g. lung, kidney),
than with the rapidly regenerating haemo-
poietic and epithelial tissues.
The conference as a whole, although with
a narrow title, touches almiost every aspect